Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis.

Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis.

We have recently shown that non-viral gene therapy can stabilise the decline of lung function in patients with cystic fibrosis (CF). However, the effect was modest, and more potent gene transfer agents are still required. Fuson protein (F)/Hemagglutinin/Neuraminidase protein (HN)-pseudotyped lentivi...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron:	Alton, E, Beekman, J, Boyd, A, Brand, J, Carlon, M, Connolly, M, Chan, M, Conlon, S, Davidson, H, Davies, J, Davies, L, Dekkers, J, Doherty, A, Gea-Sorli, S, Gill, D, Griesenbach, U, Hasegawa, M, Higgins, T, Hironaka, T, Hyndman, L, McLachlan, G, Inoue, M, Hyde, S, Innes, J, Maher, T, Moran, C, Meng, C, Paul-Smith, M, Pringle, I, Pytel, K, Rodriguez-Martinez, A, Schmidt, A, Stevenson, B, Sumner-Jones, S, Toshner, R, Tsugumine, S, Wasowicz, M, Zhu, J
Fformat:	Journal article
Iaith:	English
Cyhoeddwyd:	BMJ Publishing Group 2016

Eitemau Tebyg

Preparation for a first-in-man lentivirus trial in cystic fibrosis patients
gan: Griesenbach, U, et al.
Cyhoeddwyd: (2016)

Moving lentiviral-based gene therapy into a first-in-man CF trial
gan: Griesenbach, D, et al.
Cyhoeddwyd: (2015)

Towards a first-in-human trial with a pseudotyped lentivirus
gan: Alton, EW, et al.
Cyhoeddwyd: (2020)

Production of SIV-F/HN: a new Lentivirus vector for CF gene therapy
gan: Hyde, S, et al.
Cyhoeddwyd: (2015)

Assessment of F/HN-pseudotyped lentivirus as a clinically relevant vector for lung gene therapy.
gan: Griesenbach, U, et al.
Cyhoeddwyd: (2012)

ASSESSMENT OF F/HN-PSEUDOTYPED LENTIVIRUS AS A CLINICALLY RELEVANT VECTOR FOR LUNG GENE THERAPY
gan: Griesenbach, U, et al.
Cyhoeddwyd: (2012)

ASSESSMENT OF F/HN-PSEUDOTYPED LENTIVIRUS IN A CLINICALLY RELEVANT VECTOR FOR LUNG GENE THERAPY
gan: Griesenbach, U, et al.
Cyhoeddwyd: (2012)

Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung.
gan: Alton, E, et al.
Cyhoeddwyd: (2014)

Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung
gan: Alton, E, et al.
Cyhoeddwyd: (2014)

Lentivirus gene therapy for autoimmune pulmonary alveolar proteinosis
gan: Palau, H, et al.
Cyhoeddwyd: (2019)

The lung as a factory to produce secreted intrapulmonary and circulatory proteins
gan: Paul-Smith, M, et al.
Cyhoeddwyd: (2017)

Cumulative CFTR expression following repeated aerosol delivery of non-viral pGM169/GL67A formulation to mouse lung
gan: Alton, E, et al.
Cyhoeddwyd: (2012)

REPEAT ADMINISTRATION OF GL67A/PGM169 IS FEASIBLE, SAFE, AND PRODUCES ENDOGENOUS LEVELS OF CFTR EXPRESSION AFTER 12 DOSES
gan: Alton, E, et al.
Cyhoeddwyd: (2012)

Lentivirus GM-CSF gene therapy for autoimmune pulmonary alveolar proteinosis
gan: Lund-Palau, H, et al.
Cyhoeddwyd: (2018)

The murine lung as a factory to produce secreted intrapulmonary and circulatory proteins
gan: Paul-Smith, M, et al.
Cyhoeddwyd: (2018)

Lentivirus GM-CSF gene therapy ameliorates autoimmune pulmonary alveolar proteinosis
gan: Lund-Palau, H, et al.
Cyhoeddwyd: (2018)

Recombinant Sendai virus vector to evaluate vector distribution in a large animal model of lung gene transfer
gan: McLachlan, G, et al.
Cyhoeddwyd: (2004)

Pre-existing immunity to human parainfluenza virus (hPIV) does not affect rSIV.F/HN-mediated transduction efficiency
gan: Pytel, K, et al.
Cyhoeddwyd: (2016)

Development of an immunocytochemical assay to detect human CFTR expression following gene therapy
gan: Davidson, H, et al.
Cyhoeddwyd: (2008)

Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung.
gan: McLachlan, G, et al.
Cyhoeddwyd: (2011)

TOXICOLOGY STUDIES IN SUPPORT OF THE UK CF GENE THERAPY CONSORTIUM'S MULTI-DOSE CLINICAL TRIAL
gan: Griesenbach, U, et al.
Cyhoeddwyd: (2011)

Caprine lentivirus in sheep milk and semen
gan: C.C.V. Lima, et al.

An immunocytochemical assay to detect human CFTR expression following gene transfer.
gan: Davidson, H, et al.
Cyhoeddwyd: (2009)

Low levels of CFTR gene transfer with F/HN pseudotyped lentivirus are sufficient to generate ion transport correction in airway cell cultures from cystic fibrosis patients
gan: Sergijenko, A, et al.
Cyhoeddwyd: (2020)

Genetic medicines for CF: Hype versus reality
gan: Alton, E, et al.
Cyhoeddwyd: (2016)

A transitional endogenous lentivirus from the genome of a basal primate and implications for lentivirus evolution.
gan: Gifford, R, et al.
Cyhoeddwyd: (2008)

OPTIMISATION OF MOLECULAR ASSAYS FOR CLINICAL TRIAL OF GL67A/PDNA DELIVERY TO NOSE AND LUNG OF CF PATIENTS
gan: Sumner-Jones, S, et al.
Cyhoeddwyd: (2009)

Gene therapy for respiratory diseases; progress and a changing context
gan: Alton, EWFW, et al.
Cyhoeddwyd: (2020)

DEVELOPMENT, PRODUCTION AND EVALUATION OF CLINICAL GRADE CFTR EXPRESSION PLASMID FOR CF LUNG GENE THERAPY
gan: Gill, DR, et al.
Cyhoeddwyd: (2010)

The safety profile of a cationic lipid-mediated cystic fibrosis gene transfer agent following repeated monthly aerosol administration to sheep
gan: Alton, E, et al.
Cyhoeddwyd: (2013)

The safety profile of a cationic lipid-mediated cystic fibrosis gene transfer agent following repeated monthly aerosol administration to sheep.
gan: Alton, E, et al.
Cyhoeddwyd: (2013)

Discovery and analysis of the first endogenous lentivirus
gan: Katzourakis, A, et al.
Cyhoeddwyd: (2007)

Discovery and analysis of the first endogenous lentivirus.
gan: Katzourakis, A, et al.
Cyhoeddwyd: (2007)

EVALUATION OF SAFETY AND GENE EXPRESSION WITH A SINGLE DOSE OF PGM169/GL67A ADMINISTERED TO THE NOSE AND LUNG OF INDIVIDUALS WITH CYSTIC FIBROSIS: THE UK CF GENE THERAPY CONSORTIUM "PILOT STUDY''
gan: Davies, J, et al.
Cyhoeddwyd: (2009)

EVALUATION OF SAFETY AND GENE EXPRESSION WITH A SINGLE DOSE OF PGM169/GL67A ADMINISTERED TO THE NOSE AND LUNG OF INDIVIDUALS WITH CF: THE UK CF GENE THERAPY CONSORTIUM "PILOT STUDY"
gan: Davies, J, et al.
Cyhoeddwyd: (2009)

SAFETY AND EXPRESSION OF A SINGLE DOSE OF LIPID-MEDIATED CFTR GENE THERAPY TO THE UPPER AND LOWER AIRWAYS OF PATIENTS WITH CYSTIC FIBROSIS
gan: Davies, G, et al.
Cyhoeddwyd: (2011)

SAFETY AND EXPRESSION OF A SINGLE DOSE OF LIPID-MEDIATED CFTR GENE THERAPY TO THE UPPER AND LOWER AIRWAYS OF PATIENTS WITH CF
gan: Davies, J, et al.
Cyhoeddwyd: (2011)

A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis
gan: Alton, E, et al.
Cyhoeddwyd: (2013)

Update on the UK CF Gene Therapy Consortium Multidoes, non-viral, gene therapy trial
gan: Alton, E, et al.
Cyhoeddwyd: (2012)

A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis.
gan: Alton, E, et al.
Cyhoeddwyd: (2013)